BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6979010)

  • 1. [Initial immunologic evaluations in breast and thyroid cancer].
    Abeatici S; Mussa A; Levis P; Sandrucci S; Storta P
    Minerva Med; 1982 Apr; 73(18):1149-54. PubMed ID: 6979010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of percentage of T-lymphocytes in blood in patients with breast and thyroid cancer.
    Smejkalová E; Sloboda J; Smejkal V; Zamrazil V
    Czech Med; 1986; 9(1):51-6. PubMed ID: 3086060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoembryonic antigen: an invaluable marker for advanced breast cancer.
    Pathak KA; Khanna R; Khanna HD; Khanna S; Gupta S; Khanna NN
    J Postgrad Med; 1996; 42(3):68-71. PubMed ID: 9715319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated CEA in breast cancer patients with overlooked medullary thyroid carcinoma.
    Andry G; Wildschutz T; Chantrain G; Bonnyns M; Dor P
    Eur J Surg Oncol; 1993 Jun; 19(3):305-8. PubMed ID: 8100201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
    Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
    Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Disorders of the immune system in benign lesions and cancer of the breast].
    Derevnina NA; Polevaia EB; Veskova TK; Trubcheninova LP; Bogatyrev VN
    Vopr Onkol; 1989; 35(7):810-6. PubMed ID: 2788960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Circulating immune complexes and immunologic reactivity in breast cancer].
    Bilynskiĭ BT; Loginskiĭ VE; Fetsich TG
    Eksp Onkol; 1984; 6(3):50-2. PubMed ID: 6333978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhythmic fluctuations of CEA serum levels in breast cancer patients.
    Jäger W; Diedrich M; Sauerbrei W; Wildt L
    Anticancer Res; 1987; 7(4B):711-5. PubMed ID: 3674759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations of serum carcinoembryonic antigen, alpha-fetoprotein and immunoglobulin levels in patients with breast cancer.
    Vântu A; Bălănescu I; Stafidov N; Voiculeţ N
    Med Interne; 1982; 20(2):151-5. PubMed ID: 6181552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dynamic sampling analysis of the immune status of breast cancer patients].
    Eremina OF; Kunitsyna TA; Sharonina AI
    Vopr Onkol; 1985; 31(6):33-7. PubMed ID: 3875181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis.
    Machens A; Ukkat J; Hauptmann S; Dralle H
    Arch Surg; 2007 Mar; 142(3):289-93; discussion 294. PubMed ID: 17372055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
    Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
    Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
    Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
    Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunologic reactivity of breast cancer patients].
    Semiglazov VF; Kondrat'ev VB; Mar'enko AI; L'vovich EG; Sofronov BN
    Vopr Onkol; 1978; 24(8):74-9. PubMed ID: 695430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cellular immunologic parameters in thyroid diseases].
    Beyer PA; Wenisch HJ; Schumm-Draeger PM; Hanisch E; Seufert RM; Encke A
    Acta Med Austriaca; 1989; 16(1):6-7. PubMed ID: 2785324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hormonal and immunological changes in breast cancers with different growth rates].
    Balmukhanov SB; Zhalgasbaeva GT; Kurralasov AK; Baisheva SA; Togaĭbaeva ZI
    Vopr Onkol; 1989; 35(11):1319-22. PubMed ID: 2609521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer.
    Jotsuka T; Okumura Y; Nakano S; Nitta H; Sato T; Miyachi M; Suzumura K; Yamashita J
    Surgery; 2004 Apr; 135(4):419-26. PubMed ID: 15041966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of breast tumor antigen-sensitive circulating T-lymphocytes by antigen-stimulated active rosette formation.
    Ramey WG; Hashim GA; Burrows WB; Swistel AJ; Munther A; Fitzpatrick HF
    Cancer Res; 1979 Dec; 39(12):4796-801. PubMed ID: 315272
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.
    Willsher PC; Beaver J; Blamey RW; Robertson JF
    Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.